Browse News
Filter News
Found 22,135 articles
-
Fierce competition. Thin pipelines. Patent cliffs. The stakes are sky-high for pharmaceutical companies and investors alike.
-
Teva Pharmaceuticals and Alvotech got the FDA’s greenlight for their biosimilar to Johnson & Johnson’s blockbuster Stelara, which will launch in the U.S. in February 2025.
-
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
-
BillionToOne Mitigating RhoGAM(R) Shortage With Unity Fetal RhD™ Non-invasive Prenatal Test
4/17/2024
BillionToOne, a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, has reached a milestone of testing over 80,000 patients for Rh incompatibility, which develops when a pregnant patient has Rh-negative blood and the baby has Rh-positive blood.
-
Domain Therapeutics Appoints Sean A. MacDonald as Chief Executive Officer
4/17/2024
Domain Therapeutics today announces the appointment of Sean A. MacDonald as its Chief Executive Officer (CEO).
-
Biologics Market Size to Hit Around USD 1. 37 Trillion By 2033
4/17/2024
According to the latest Research by Nova One Advisor, the global biologics market size was exhibited at USD 511.04 billion in 2024 and is projected to hit around USD 1,374.51 billion by 2033, growing at a CAGR of 10.4% during the forecast period 2024 to 2033.
-
Essential Pharma Announces the Acquisition of Reminyl® (galantamine hydrobromide) Oral Capsules
4/17/2024
Essential Pharma announces that it has completed the acquisition of Reminyl® oral capsules from Janssen Pharmaceutica NV, a Johnson & Johnson company.
-
MustGrow Biologics to Present at the Planet MicroCap Showcase
4/17/2024
Saskatoon, Saskatchewan--(Newsfile Corp. - April 17, 2024) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow") is pleased to announce...
-
Despite the strong performance of its cancer portfolio, Johnson & Johnson on Tuesday reported Stelara sales of $2.45 billion in the first quarter of 2024, falling short of Wall Street expectations of $2.6 billion.
-
Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer
4/16/2024
Recursion announced Najat Khan, PhD, will be its Chief R&D Officer and Chief Commercial Officer.
-
Johnson & Johnson Announces 62nd Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 4.2%
4/16/2024
Johnson & Johnson announced that its Board of Directors has declared a 4.2% increase in the quarterly dividend, from $1.19 per share to $1.24 per share, marking the 62nd year of consecutive increases.
-
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
4/16/2024
Alvotech and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., announced that the U.S. Food and Drug Administration has approved SELARSDI injection for subcutaneous use, as a biosimilar to Stelara®, for the treatment of moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients 6 years and older.
-
Xstim, Inc. Receives FDA Approval for Xstim™ Spine Fusion Stimulator.
4/16/2024
Xstim, Inc., a pioneering developer and manufacturer of cutting-edge bone growth stimulation systems, is thrilled to announce its recent Premarket Application approval from the U.S. Food and Drug Administration for Xstim™ Spine Fusion Stimulator.
-
IMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial
4/16/2024
Updated exploratory results from the TOPAZ-1 Phase III trial showed AstraZeneca’s IMFINZI ® (durvalumab) in combination with standard-of-care chemotherapy demonstrated a clinically meaningful long-term overall survival (OS) benefit at three years for patients with advanced biliary tract cancer (BTC).
-
CORRECTING and REPLACING Johnson & Johnson Reports Q1 2024 Results
4/16/2024
Johnson & Johnson announced results for first-quarter 2024. “Johnson & Johnson’s solid first quarter performance reflects our sharpened focus and the progress in our portfolio and pipeline,” said Joaquin Duato, Chairman and Chief Executive Officer.
-
Johnson & Johnson Reports Q1 2024 Results
4/16/2024
Johnson & Johnson announced results for first-quarter 2024. “Johnson & Johnson’s solid first quarter performance reflects our sharpened focus and the progress in our portfolio and pipeline,” said Joaquin Duato, Chairman and Chief Executive Officer.
-
Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma
4/15/2024
Prothena Corporation plc announced the publication related to the mechanism of action, pharmacological characteristics, and clinical utility of birtamimab, a potential best-in-class anti-amyloid treatment for AL amyloidosis.
-
First Interim Analysis of PROSPER Study Details Patient-Reported Symptom Burden of Mycosis Fungoides and Sézary Syndrome
4/15/2024
Professor Julia Scarisbrick of University of Birmingham on Friday, April 12, 2024, presented interim findings from the Kyowa Kirin, Inc. (Kyowa Kirin, TSE: 4151)-sponsored study, "Real-World Observational Study of Mogamulizumab in Adult Patients with Mycosis Fungoides and Sézary Syndrome (PROSPER)".
-
AviadoBio Announces First Patient Treated in ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations
4/15/2024
AVB-101 is an investigational gene therapy designed to deliver a functional copy of the GRN gene directly to the brain, thus restoring progranulin levels and potentially stopping disease progression.
-
In 2023, the FDA greenlit 55 new drugs and 34 cell and gene therapies. Follow along as BioSpace keeps you up to date on all of the FDA's decisions in 2024.